TABLE 4.
Univariate analysis of risk factors associated with progression-free survival.
| Characteristic | HR | 95% CI | p value | |
|---|---|---|---|---|
| Gender | F/M | 1.030 | 0.743–1.428 | 0.858 |
| Age (years) | >55/≤55 | 0.911 | 0.728–1.140 | 0.415 |
| ECOG | 1/0 | 0.562 | 0.139–2.273 | 0.419 |
| Etiology | HBV/others | 1.030 | 0.745–1.423 | 0.859 |
| Cirrhosis | Yes/no | 0.935 | 0.734–1.193 | 0.591 |
| Tumor size (cm) | >5/≤5 | 1.588 | 1.262–1.997 | <0.001 |
| No. of nodules | ≥3/<3 | 1.020 | 0.813–1.280 | 0.865 |
| PVTT | Yes/no | 1.576 | 1.234–2.014 | <0.001 |
| Hepatic vein invasion | Yes/no | 1.477 | 1.043–2.093 | 0.028 |
| Child-Pugh class | B/A | 1.313 | 0.488–3.529 | 0.589 |
| ALBI grade | 3/2/1 | 1.169 | 0.941–1.452 | 0.158 |
| Tumor distribution | Bilobar/unilobar | 0.915 | 0.719–1.165 | 0.472 |
| Extrahepatic spread | Yes/no | 2.091 | 1.442–3.031 | <0.001 |
| AFP (ng/dl) | >200/≤200 | 1.321 | 1.053–1.656 | 0.016 |
| AST (U/L) | >40/≤40 | 1.545 | 1.229–1.942 | <0.001 |
| ALT (U/L) | >40/≤40 | 1.033 | 0.822–1.297 | 0.783 |
| Albumin (g/L) | >35/≤35 | 0.751 | 0.575–0.981 | 0.036 |
| TBIL (umol/L) | >17.1/≤17.1 | 1.079 | 0.778–1.499 | 0.648 |
| NLR | ≥2.42/<2.42 | 1.533 | 1.220–1.926 | <0.001 |
| PLR | ≥100/<100 | 1.599 | 1.270–2.013 | <0.001 |
| AST/ALT | >1.18/≤1.18 | 1.424 | 1.135–1.787 | 0.002 |
AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PVTT, portal vein tumor thrombus; TBIL, total bilirubin; HR, hazard ratio; CI, confidence interval.